Omar Dukar, MD
Ophthalmology · Evansville, INNPI 1609875723
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,157 of the $43,074 with a category attached, or 79.3%. 19 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 56.4% of the total. Reporting peaked in 2019 at $20,608 and has fallen 98.6% since, to $280 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $186.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$24K
- AbbVie$9K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$7K
- Bausch & Lomb Americas Inc.$602
- Alcon$491
- Regeneron Healthcare Solutions, Inc.$201
- plus $826 from 13 others
What the payments were for
- Consulting fees$5001%
- Speaking & faculty fees$34,15779%
- Travel & lodging$3,5348%
- Food & beverage$4,88311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 32 | $24,298 |
| AbbVie(2 entities) | 91 | $9,442 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $7,214 |
| Bausch & Lomb Americas Inc. | 29 | $602 |
| Alcon | 18 | $491 |
| Regeneron Healthcare Solutions, Inc. | 4 | $201 |
| Biotissue Holdings Inc. | 3 | $141 |
| Sun Pharmaceutical Industries Inc. | 7 | $118 |
| Kala Pharmaceuticals, Inc. | 4 | $92 |
| Novartis | 5 | $91 |
| Regeneron | 1 | $75 |
| ANI Pharmaceuticals, Inc. | 1 | $68 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Amgen(2 entities) | 3 | $55 |
| NEW World Medical,inc. | 2 | $30 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Dompe US, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$23,861
- Rocklatan$23,861
- LUMIGAN$7,279
- VYZULTA$6,854
- COMBIGAN$3,198
- ALPHAGAN P$500
- Luxor$139
- Prokera$130
- AmnioGraft$130
How this compares
$43,074 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 802 | $370,143 |
| RhopressaNetarsudil Mesylate | 580 | $259,030 |
| RestasisCyclosporine | 74 | $77,111 |
| RocklatanNetarsudil Mesylat/Latanoprost | 168 | $74,606 |
| CombiganBrimonidine Tartrate/Timolol | 184 | $67,896 |
| Alphagan PBrimonidine Tartrate | 82 | $33,525 |
| Travoprost | 231 | $33,068 |
| XiidraLifitegrast | 39 | $32,287 |
| VyzultaLatanoprostene Bunod | 76 | $29,657 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,393 | $22,573 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 137 | $18,279 |
| Latanoprost | 2,006 | $17,888 |
| Prednisolone Acetate | 663 | $15,895 |
| Brimonidine Tartrate | 906 | $14,548 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $14,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $9,442 | $548,6751,142 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $24,298 | $333,636748 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $602 | $61,944115 claims |
| AlconSimbrinza | $491 | $14,19464 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $7,214 | $3,07112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Evansville
- Dwight SilveraEvansville$28K
- David MalitzEvansville$12K
- Andrew StrandEvansville$12K
- Drew SommervilleEvansville$8K
- Matthew BoyerEvansville$6K
- Karishma HabbuEvansville$4K
- Jonathan WeyerEvansville$4K
- Sally PrimusEvansville$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.